相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tofacitinib for the treatment of active ankylosing spondylitis in adults
Raagav Mohanakrishnan et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2022)
Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis
Cecilia C. Ayala-Aguilera et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Kincore: a web resource for structural classification of protein kinases and their inhibitors
Vivek Modi et al.
NUCLEIC ACIDS RESEARCH (2022)
Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2022)
The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience
Mikhail M. Kostik et al.
FRONTIERS IN PEDIATRICS (2022)
Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials
Elena Muensterman et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2022)
The suitability of treating atopic dermatitis with Janus kinase inhibitors
Shanthi Narla et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2022)
Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2022)
Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation
Caleb R. Glassman et al.
SCIENCE (2022)
JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies
Bilal Rah et al.
FRONTIERS IN PHARMACOLOGY (2022)
A Comprehensive Overview of Globally Approved JAK Inhibitors
Ahmed M. Shawky et al.
PHARMACEUTICS (2022)
Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy
Maria Napolitano et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2022)
The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19
Peter J. Richardson et al.
VACCINES (2022)
Abrocitinib: First Approval
Emma D. Deeks et al.
DRUGS (2021)
Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2021)
Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2021)
Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof
Ryan R. Davis et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children: A Retrospective Study
Wenli Yang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2021)
PERK Pathway and Neurodegenerative Disease: To Inhibit or to Activate?
Talya Shacham et al.
BIOMOLECULES (2021)
Target-Based Evaluation of Drug-Like Properties and Ligand Efficiencies
Paul D. Leeson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Kinase drug discovery 20 years after imatinib: progress and future directions
Philip Cohen et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia
Yunchao Chang et al.
BLOOD (2021)
GSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways
Stefania Demuro et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Trends in kinase drug discovery: targets, indications and inhibitor design
Misty M. Attwood et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2021)
Hydrophobic and polar interactions of FDA-approved small molecule protein kinase inhibitors with their target enzymes
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2021)
The JAK/STAT signaling pathway: from bench to clinic
Xiaoyi Hu et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2020)
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2020)
The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2020)
Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates
Adriana Coricello et al.
MOLECULES (2020)
The regulation of JAKs in cytokine signaling and its breakdown in disease
Henrik M. Hammaren et al.
CYTOKINE (2019)
Targeting ERK1/2 protein-serine/threonine kinases in human cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
The Jakinibs in systemic lupus erythematosus: progress and prospects
Chi Chiu Mok
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Regulation of osteoclast function via Rho-Pkn3-c-Src pathways
Shunsuke Uehara et al.
JOURNAL OF ORAL BIOSCIENCES (2019)
Identification of N-{cis-3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)aminolcyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases
Michael L. Vazquez et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials
Fabrice Carles et al.
MOLECULES (2018)
Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers
Robert Roskoski et al.
PHARMACOLOGICAL RESEARCH (2018)
The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2018)
The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2018)
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2018)
Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2017)
ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2017)
Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2017)
Guidelines for preparing color figures for everyone including the colorblind
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2017)
Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2017)
AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective
Samuel H. Myers et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods
Sean Ekins et al.
PHARMACEUTICAL RESEARCH (2016)
Molecular inflation, attrition and the rule of five
Paul D. Leeson
ADVANCED DRUG DELIVERY REVIEWS (2016)
Quality guidelines for oral drug candidates: dose, solubility and lipophilicity
Martin K. Bayliss et al.
DRUG DISCOVERY TODAY (2016)
Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2016)
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2016)
Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2016)
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2016)
JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications
Lorraine Springuel et al.
HAEMATOLOGICA (2015)
A historical overview of protein kinases and their targeted small molecule inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2015)
Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2015)
JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications
Lorraine Springuel et al.
HAEMATOLOGICA (2015)
The molecular regulation of Janus kinase (JAK) activation
Jeffrey J. Babon et al.
BIOCHEMICAL JOURNAL (2014)
KLIFS: A Knowledge-Based Structural Database To Navigate Kinase-Ligand Interaction Space
Oscar P. J. van Linden et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Physicochemical Descriptors of Aromatic Character and Their Use in Drug Discovery
Timothy J. Ritchie et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
The role of ligand efficiency metrics in drug discovery
Andrew L. Hopkins et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
The ErbB/HER family of protein-tyrosine kinases and cancer
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition
Patrick J. Lupardus et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders
Robert Roskoski
EXPERT OPINION ON DRUG DISCOVERY (2013)
Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2013)
Approaches to discover non-ATP site kinase inhibitors
Lori Krim Gavrin et al.
MEDCHEMCOMM (2013)
Deciphering the Structural Basis of Eukaryotic Protein Kinase Regulation
Hiruy S. Meharena et al.
PLOS BIOLOGY (2013)
MEK1/2 dual-specificity protein kinases: Structure and regulation
Robert Roskoski
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis
John Mascarenhas et al.
CLINICAL CANCER RESEARCH (2012)
New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors
Vandana Lamba et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
ERK1/2 MAP kinases: Structure, function, and regulation
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2012)
Evolution of the eukaryotic protein kinases as dynamic molecular switches
Susan S. Taylor et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2012)
The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
Arvin C. Dar et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 80 (2011)
RAF protein-serine/threonine kinases: Structure and regulation
Robert Roskoski
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Through the Gatekeeper Door: Exploiting the Active Kinase Conformation
Fabio Zuccotto et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6
Jill E. Chrencik et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
Selective p38α Inhibitors Clinically Evaluated for the Treatment of Chronic Inflammatory Disorders
David M. Goldstein et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains
Neal K. Williams et al.
JOURNAL OF MOLECULAR BIOLOGY (2009)
A helix scaffold for the assembly of active protein kinases
Alexandr P. Kornev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The JAK kinases: Not just another kinase drug discovery target
Andrew F. Wilks
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2008)
The influence of drug-like concepts on decision-making in medicinal chemistry
Paul D. Leeson et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors
Jeffrey Jie-Lou Liao
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism
Alexandr P. Kornev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Targeting Rho and Rho-kinase in the treatment of cardiovascular disease
K Budzyn et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2006)
Tyrosine phosphorylation of the Janus kinase 2 activation loop is essential for a high-activity catalytic state but dispensable for a basal catalytic state
K Chatti et al.
BIOCHEMISTRY (2004)
Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia
BL Roth et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
The Janus kinases (Jaks)
K Yamaoka et al.
GENOME BIOLOGY (2004)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
Molecular properties that influence the oral bioavailability of drug candidates
DF Veber et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling
J Irie-Sasaki et al.
NATURE (2001)
分享论文
